Literature DB >> 20413545

A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis.

O Nishiyama1, H Taniguchi, Y Kondoh, T Kimura, K Kato, K Kataoka, T Ogawa, F Watanabe, S Arizono.   

Abstract

The prognosis in idiopathic pulmonary fibrosis (IPF) is poor. No therapy has been shown to prolong survival. The objective of this study was to examine the prognostic significance of dyspnoea in daily living at baseline in IPF using a simple assessment tool. 93 consecutive patients with IPF, who had undergone evaluation at diagnosis, were included. The level of dyspnoea was assessed using the modified Medical Research Council (MRC) scale. The relationship between data at baseline and survival was examined. A univariate Cox proportional-hazard model showed that forced vital capacity % predicted (hazard ratio (HR) 0.965, 95% CI 0.948-0.982; p<0.0001), diffusing capacity of the lung for carbon monoxide % predicted (HR 0.978, 95% CI 0.963-0.993; p = 0.0041), baseline arterial oxygen tension (HR 0.963, 95% CI 0.938-0.989; p = 0.0060) and modified MRC score (HR 2.402, 95% CI 1.495-3.858; p = 0.0003) were significantly predictive of survival. All variables of the 6-min walk test, including walk distance (HR 0.995, 95% CI 0.992-0.998; p = 0.0020), the lowest arterial oxygen saturation measured by pulse oximetry (S(p,O(2))) (HR 0.944, 95% CI 0.918-0.972; p<0.0001) and the Borg scale (HR 1.285, 95% CI 1.091-1.514; p = 0.0027), were also significant. With stepwise, multivariate Cox proportional analysis, the modified MRC score (HR 2.181, 95% CI 1.333-3.568; p = 0.0019) and the lowest S(p,O(2)) during the 6-min walk test (HR 0.952, 95% CI 0.924-0.981; p = 0.0014) were the most significant. Dyspnoea in daily living, assessed with the modified MRC scale at baseline, provides additional prognostic information for patients with IPF.

Entities:  

Mesh:

Year:  2010        PMID: 20413545     DOI: 10.1183/09031936.00152609

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  53 in total

1.  Prognostic value of forced expiratory volume in 1 second/forced vital capacity in idiopathic pulmonary fibrosis.

Authors:  Osamu Nishiyama; Ryo Yamazaki; Akiko Sano; Toshiyuki Yamagata; Hiroyuki Sano; Takashi Iwanaga; Yuji Higashimoto; Hiroaki Kume; Yuji Tohda
Journal:  Chron Respir Dis       Date:  2015-09-15       Impact factor: 2.444

2.  Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis.

Authors:  Susan E Yount; Jennifer L Beaumont; Shih-Yin Chen; Karen Kaiser; Katy Wortman; David L Van Brunt; Jeffrey Swigris; David Cella
Journal:  Lung       Date:  2016-02-09       Impact factor: 2.584

3.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

Review 4.  Clinical Trial Design Issues in Systemic Sclerosis: an Update.

Authors:  Jessica K Gordon; Robyn T Domsic
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

Review 5.  Optimizing quality of life in patients with idiopathic pulmonary fibrosis.

Authors:  Mirjam J G van Manen; J J Miranda Geelhoed; Nelleke C Tak; Marlies S Wijsenbeek
Journal:  Ther Adv Respir Dis       Date:  2017-01-01       Impact factor: 4.031

6.  Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity.

Authors:  Hana Serajeddini; Paola Rogliani; Marco Mura
Journal:  Lung       Date:  2018-08-27       Impact factor: 2.584

7.  The Minimal Important Difference in Borg Dyspnea Score in Pulmonary Arterial Hypertension.

Authors:  Rubina M Khair; Chisom Nwaneri; Rachel L Damico; Todd Kolb; Paul M Hassoun; Stephen C Mathai
Journal:  Ann Am Thorac Soc       Date:  2016-06

8.  Measurement of dyspnea in patients with obstructive sleep apnea.

Authors:  Kensaku Aihara; Toru Oga; Chikara Yoshimura; Takefumi Hitomi; Yuichi Chihara; Yuka Harada; Kimihiko Murase; Yoshiro Toyama; Kiminobu Tanizawa; Tomohiro Handa; Tomomasa Tsuboi; Michiaki Mishima; Kazuo Chin
Journal:  Sleep Breath       Date:  2012-08-03       Impact factor: 2.816

Review 9.  Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic Disease.

Authors:  Wim A Wuyts; Marlies Wijsenbeek; Benjamin Bondue; Demosthenes Bouros; Paul Bresser; Carlos Robalo Cordeiro; Ole Hilberg; Jesper Magnusson; Effrosyni D Manali; António Morais; Spyridon Papiris; Saher Shaker; Marcel Veltkamp; Elisabeth Bendstrup
Journal:  Respiration       Date:  2019-12-12       Impact factor: 3.580

Review 10.  A systematic review of literature to evaluate the burden of physical and psychological symptoms and palliative care in patients diagnosed with idiopathic pulmonary fibrosis.

Authors:  M F van Jaarsveld; L Gwyther
Journal:  Afr J Thorac Crit Care Med       Date:  2019-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.